Moreover, primary cells obtained from malignant ascites or pleural effusion of refractory B-cell lymphoma patients showed significantly more increased expression of FOXO4 than that of a patient who completely responded to 1st line treatment (Figure 3E). This evidence concerns the gene FOXO4 and B-cell non-Hodgkin lymphoma.